Literature DB >> 20586698

Antioxidant approaches for the treatment of Alzheimer's disease.

Hyun Pil Lee1, Xiongwei Zhu, Gemma Casadesus, Rudy J Castellani, Akihiko Nunomura, Mark A Smith, Hyoung-gon Lee, George Perry.   

Abstract

Oxidative stress is an important factor, and one that acts in the earliest stages, of Alzheimer's disease (AD) pathogenesis. The reduction of oxidative stress has been tested as a therapy for AD. While the trial of vitamin E supplementation in moderately severe AD is the most promising so far, it also reveals the limitations of general antioxidant therapies that simply lower oxidative stress and, therefore, the complexity of the redox system. The multiple contributing factors that foster the clinical manifestations of AD should be considered when designing antioxidative stress therapy. In this article, we discuss the multiple pathogenic mechanisms of oxidative stress in AD and the potential targeting approaches.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20586698     DOI: 10.1586/ern.10.74

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  37 in total

Review 1.  Targeting NOX enzymes in the central nervous system: therapeutic opportunities.

Authors:  Silvia Sorce; Karl-Heinz Krause; Vincent Jaquet
Journal:  Cell Mol Life Sci       Date:  2012-05-30       Impact factor: 9.261

Review 2.  Alzheimer mechanisms and therapeutic strategies.

Authors:  Yadong Huang; Lennart Mucke
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

3.  Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation.

Authors:  Ira T Lott; Eric Doran; Vinh Q Nguyen; Anne Tournay; Elizabeth Head; Daniel L Gillen
Journal:  Am J Med Genet A       Date:  2011-07-07       Impact factor: 2.802

4.  Genistein inhibits mitochondrial-targeted oxidative damage induced by beta-amyloid peptide 25-35 in PC12 cells.

Authors:  Yuan-Di Xi; Huan-Ling Yu; Wei-Wei Ma; Bing-Jie Ding; Juan Ding; Lin-Hong Yuan; Jin-Fang Feng; Rong Xiao
Journal:  J Bioenerg Biomembr       Date:  2011-07-06       Impact factor: 2.945

5.  The amyloid precursor protein (APP) family members are key players in S-adenosylmethionine formation by MAT2A and modify BACE1 and PSEN1 gene expression-relevance for Alzheimer's disease.

Authors:  Andreas Schrötter; Kathy Pfeiffer; Fouzi El Magraoui; Harald W Platta; Ralf Erdmann; Helmut E Meyer; Rupert Egensperger; Katrin Marcus; Thorsten Müller
Journal:  Mol Cell Proteomics       Date:  2012-08-09       Impact factor: 5.911

6.  Effect of one-year vitamin C- and E-supplementation on cerebrospinal fluid oxidation parameters and clinical course in Alzheimer's disease.

Authors:  Sönke Arlt; Tomas Müller-Thomsen; Ulrike Beisiegel; Anatol Kontush
Journal:  Neurochem Res       Date:  2012-08-10       Impact factor: 3.996

7.  A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice.

Authors:  Varsha Shukla; Ya-Li Zheng; Santosh K Mishra; Niranjana D Amin; Joseph Steiner; Philip Grant; Sashi Kesavapany; Harish C Pant
Journal:  FASEB J       Date:  2012-10-04       Impact factor: 5.191

8.  Neuroprotective effects of Hu-Yi-Neng, a diet supplement, on SH-SY5Y human neuroblastoma cells.

Authors:  Y-H Yang; T-J Hsieh; M-L Tsai; C-H Chen; H-T Lin; S-J Wu
Journal:  J Nutr Health Aging       Date:  2014       Impact factor: 4.075

Review 9.  Multi-Target Drug Candidates for Multifactorial Alzheimer's Disease: AChE and NMDAR as Molecular Targets.

Authors:  Md Sahab Uddin; Abdullah Al Mamun; Md Tanvir Kabir; Ghulam Md Ashraf; May N Bin-Jumah; Mohamed M Abdel-Daim
Journal:  Mol Neurobiol       Date:  2020-09-15       Impact factor: 5.590

Review 10.  Vitamin E for Alzheimer's dementia and mild cognitive impairment.

Authors:  Nicolas Farina; Mokhtar Gad El Kareem Nasr Isaac; Annalie R Clark; Jennifer Rusted; Naji Tabet
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.